AbbVie's Pain Is Sanofi's and Regeneron's Gain
The U.S. Food and Drug Administration recently announced that it's requiring a warning about potential health issues linked to JAK inhibitors. The agency is also restricting the use of the drugs to patients who were unsuccessfully treated with at least one TNF inhibitor.
This decision especially hurts AbbVie (NYSE: ABBV). The big pharma company was counting on JAK inhibitor Rinvoq to deliver strong sales growth. In this Motley Fool Live video recorded on Sept. 8, Motley Fool contributors Keith Speights and Brian Orelli discuss how the FDA decision that's causing pain for AbbVie should help Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN).
Source Fool.com
